The availability of rapid and quantitative titration assays for retroviral vectors is important, especially in the context of clinical applications. In this report, we describe a novel assay to titrate lentiviral and gamma retroviral vectors. This rapid assay is based on protein fragment complementation involving the N-terminal (Bla1) and the C-terminal (Bla2) fragments of TEM-1 b-lactamase (BLAK). The Bla1 protein fragment is incorporated in the vector's envelope during vector production. Bla1-bearing vectors are titrated on Bla2-expressing cells. Upon transduction, Bla1 and Bla2 heterodimerize and restore BLAK's enzymatic function. The enzymatic activity of BLAK is quantified by flow cytometry using the green fluorescent CCF2/AM substrate, which is converted into a blue fluorescent product. The enzymatic conversion of the CCF2/AM substrate was found to be directly related to vector entry, as a neutralizing antibody completely blocked the conversion. The titers obtained using this rapid assay correlated well with the titers measured by functional transduction assays. The whole assay can be finished within 8 h. Thus, it is considerably less time consuming compared with other transduction-based titration assays for lentiviral and gamma retroviral vectors.
INTRODUCTION
Retroviral vectors include vectors based on gamma retroviruses and on lentiviruses. They provide powerful tools for gene delivery in vitro, ex vivo and in vivo. The principal advantages of retroviral vectors include high efficiency of transgene delivery and integration into the host cell genome and sustained transgene expression in target cells. Gamma retroviral vectors are well developed and have been used in clinical trials for over 2 decades now. 1 Lentiviral vectors are becoming increasingly popular because, in contrast to gamma retroviral vectors, they can transduce dividing as well as non-dividing cells. 2 Also, there have been no reports so far for lentiviral vector-mediated insertional mutagenesis events that resulted in clinical adverse events. 3, 4 Quantitative assays to determine the titers of retroviral vectors are important, especially in the context of clinical applications. For example, because of safety reasons, the FDA recommends that the number of retroviral vector copies per cell be within a defined and reproducible range. To achieve this goal, vector titers must be determined before transduction of the desired target cells. The currently available titration assays can be divided into two major categories: functional titration assays and non-functional ones. 5 The functional titration assays are based on vector DNA copy numbers in target cells 6, 7 or on the expression of transgenes in target cells. 8 --10,7,11 One drawback of these assays is that they are time-consuming. The non-functional assays measure the quantity of vector components, for example, vector RNA copies, 12, 6, 13 the capsid protein p24 (for HIV-1-based lentiviral vectors), 14 or reverse transcriptase activity. 15 These non-functional assays typically are rapid, but do not always reflect functional vector titers. For example, vectors either lacking the genome or the envelope protein do not reveal functional titers but p24-based physical titers can still be obtained. 10 In this report, we describe a novel titration assay for retroviral vectors that relies on entry of vector particles into target cells. It is based on protein fragment complementation involving the N-terminal (Bla1) and the C-terminal (Bla2) fragments of TEM-1 b-lactamase (BLAK), fused to the human FKBP-rapamycin-binding (FRB) protein and the FKBP12 (FK506)-binding protein, respectively. 16 In addition, a 15-amino acid membrane-anchoring sequence (S15) derived from c-Src was fused to the N-terminus of the FRB-Bla1 protein for membrane targeting. 17 ,18 S15-FRB-Bla1 is incorporated into the vector's envelope during production. For titration, FKBP12-Bla2-expressing human embryonic kidney (HEK) 293 cells are transduced with S15-FRB-Bla-bearing vectors. Upon transduction, Bla1 enters the target cell and heterodimerizes with Bla2 through FRB and FKBP in the presence of rapamycin, restoring BLAK enzymatic activity, which can be detected using the fluorescent CCF2/AM substrate. 19 The percentage of transduced cells is quantified by flow cytometry and forms the basis to calculate vector titers.
RESULTS
Overview of the titration assay based on BLAK protein fragment complementation The titration assay is outlined in Figure 1 . The system involves the N-terminal (Bla1, amino acids 26 --199) and C-terminal (Bla2, amino acids 200 --263) fragments of TEM-1 BLAK fused to the C-terminal ends of the engineered FRB (FKBP rapamycin binding domain, T2098L) and FKBP12 (FK506 binding protein 12) domains, respectively. 20 FRB and FKBP12 form a heterodimeric complex in the presence of rapamycin, thereby restoring BLAK enzymatic activity through protein fragment complementation. 16 To promote the incorporation of S15-FRB-Bla1 into lentiviral and gamma retroviral vector particles, a 15-amino acid membrane-anchoring sequence (S15) derived from c-Src 17, 18 was fused to the Nterminus of the FRB-Bla1 protein ( Figure 1a) ; for virion incorporation, the pS15-FRB-Bla1 plasmid is co-transfected together with a vector plasmid, a packaging plasmid and an envelope-encoding plasmid into HEK 293T cells during vector production.
For vector titration, FKBP12-Bla2 is stably expressed in the cytoplasm of the target cells, such as HEK 293 cells. Upon fusion of the vector's membrane with target cell membranes, the vectorassociated FRB-Bla1 will enter the cells and heterodimerize with Bla2 present in the target cells, resulting in enzymatically active BLAK. 16 BLAK converts the green fluorescent substrate CCF2 into a blue fluorescent product (Figure 1b) . The lipophilic substrate precursor, CCF2/AM, is taken up by cells and cleaved by cellular esterases, generating the negatively charged CCF2, which is retained in the cytosol. 19 Vector titers can be calculated from the percentage of blue cells, which can be determined by flow cytometry.
Testing of fragment complementation efficiency in transiently transfected cells BLAK fragment complementation efficiency was tested in HEK 293T cells transiently transfected with either the S15-FRB-Bla1-encoding plasmid or the FKBP12-Bla2-encoding plasmid, or both plasmids together. A plasmid encoding wild-type BLAK-was used as a positive control. Three days after transfection, cells were loaded with rapamycin and the CCF2/AM substrate. Figure 2a (top panels) shows that 54.4% of the cells were blue when both plasmids were co-transfected; there were no blue cells when either of the plasmid was transfected alone. A similar percentage of blue fluorescence-emitting cells (58.6%) was observed for the positive control, a wild-type BLAK-encoding plasmid (Figure 2a) , suggesting that fragment complementation is efficient.
We next tested the effects of the concentration and the loading time of the CCF2/AM substrate on the yield of blue fluorescenceemitting cells. To do this, HEK 293T cells were transiently transfected with a plasmid encoding the wild-type BLAK, and 2 days later, the cells were loaded with the CCF2/AM substrate at concentrations of 0.2 mM or 1 mM for 1 or 2 h (Figure 2b) . The results obtained indicated that a CCF2/AM substrate concentration as low as 0.2 mM and a loading time as short as 1 h resulted in signals robust enough for flow-cytometric detection.
Production of Bla1-containing lentiviral and gamma retroviral vectors HEK 293T cells were transiently transfected with lentiviral or gamma retroviral packaging and transgene-containing plasmids and a plasmid encoding VSV-G, with or without the S15-FRB-Bla1-encoding plasmid. The viral vectors were collected 60 h later and concentrated by ultracentrifugation through a 20% sucrose cushion to get rid of soluble proteins. The incorporation of S15-FRB-Bla1 into vector particles was checked by western When HEK 293 target cells expressing FKBP12-Bla2 are transduced with vectors bearing S15-FRB-Bla1, BLAK activity is restored. BLAK enzymatic activity can be detected using CCF2 as a substrate. 19 When the target cells are loaded with the lipophilic CCF2/AM substrate, cytoplasmic esterases will rapidly convert it to the negatively charged CCF2 product, which will be retained in the cytosol. Hydrolysis of CCF2 by BLAK results in cells emitting blue fluorescence, 19 which can be determined by flow cytometry or fluorescence microscopy. The color reproduction of this figure is available at the Gene Therapy journal online.
blotting with an antibody against TEM-1 BLAK. A band of 35 kDa, consistent with the size of S15-FRB-Bla1, was detected in HIV-1 lentiviral and moloney murine leukemia virus (MLV) gamma retroviral vector pellets when the S15-FRB-Bla1-encoding plasmid was present but not in its absence, indicating that S15-FRB-Bla1 was indeed associated with vector particles (Figure 3 ). HIV-1 capsid protein p24 and MLV capsid protein P30 levels were comparable whether or not pS15-FRB-Bla1 was included during vector production. The functional titers of the S15-FRB-Bla1-bearing vectors measured by EGFP reporter gene expression were comparable to those obtained using S15-FRB-Bla1-negative vectors (data not shown). Sensitivity and specificity of the fragment complementation-based titration assay To optimize the sensitivity of the titration assay, different transduction methods with or without spinoculation, 21 different transduction times and different substrate development times were investigated ( Figure 4 ). Representative FACS data are shown in Figure 4a . The data obtained revealed that spinoculation, a 37 1C incubation step after spinoculation, and a development step after substrate loading all increased the sensitivity of the assay (Figure 4b ). However, in order to be able to perform the assay in 1 workday, conditions involving a sub-optimal but reasonable sensitivity were chosen; these included 1 h of spinoculation, 1 h of incubation at 37 1C, 1 h of substrate loading, and 2 h of substrate development. The final protocol of the titration assay is outlined in Table 1 .
To confirm that the assay signal detected was due to vector uptake by target cells, S15-FRB-Bla1-carrying lentiviral vectors bearing VSV-G on their surface were pretreated with an anti-VSV-G-neutralizing monoclonal antibody (8G5F11) 22 before transduction of FKBP12-Bla2-expressing HEK 293 cells. Figure 5 shows that the percentage of cells emitting blue fluorescence dropped to background levels, suggesting that the signal detected resulted from vector entry into the target cells.
Correlation of the assay readout with functional vector titers We next investigated whether the readout of the fragment complementation-based titration assay correlates with functional titers of lentiviral and gamma retroviral vectors. To do this, HEK 293 FKBP12-Bla2 cells were transduced using serially diluted EGFPencoding lentiviral or MLV gamma retroviral vectors, which bore S15-FRB-Bla1. After 1 h of spinoculation and 1 h of incubation at 37 1C, the cells were either used for fragment complementationbased titration following the procedures outlined in Table 1 , or incubated at 37 1C for another 48 h before determining EGFP functional titers using flow cytometry. The data presented in Figure 6 , panels a and b show that the percentage of cells emitting blue fluorescence correlated well with functional EGFP titers, with R 2 values for HIV-1 lentiviral and MLV gamma retroviral vectors of 0.9825 and 0.985, respectively. The results presented in Figure 6 show that multiple infectious vector particles are needed for a cell to produce a blue fluorescence signal. For example, 5 Â 10 6 infectious lentiviral vector particles resulted in about 3 Â 10 5 blue cells (Figure 6a ).
Effects of ultracentrifugation and freezing and thawing on assay performance All the above experiments were performed using vectors concentrated by ultracentrifugation. It was important to determine whether the assay can also work with unconcentrated crude supernatants. Also, freezing and thawing may decrease vector titers; thus it was important to determine whether freezing and thawing would affect this assay's readout. Using the HIV-1 lentiviral vector as an example, we tested the effects of ultracentrifugation and freezing and thawing cycles on the assay. VSV-G pseudotyped HIV-1 lentiviral vectors containing S15-FRBBla1 were produced and 6 aliquots were made, three of Figure 5 . Testing the specificity of the fragment complementation assay. S15-FRB-Bla1-containing lentiviral vector particles were pre-incubated with or without 5 mg ml --1 of the anti-VSV-G monoclonal antibody 8G5F11 (ref. 22) for 1 h at room temperature before adding them to the target cells for titration using the assay conditions described Figure 4 . Two replicates were tested for each condition. The average of the percentages of blue fluorescence-emitting cells±s.d. is shown. Figure 6 . Correlation of BLAK-based titers with functional lentiviral and gamma retroviral vector titers. (a) Lentiviral vectors. S15-FRB-Bla1-containing lentiviral vectors were produced and concentrated 300 times as described under Materials and Methods. The vector stock was diluted 100, 200, 400, 800 or 1600-fold. Two replicates were tested for each dilution and the percentage of cells containing cleaved CCF2 was determined according to the conditions listed in Figure 4 and in Table 1 . The average percentages of cells containing cleaved CCF2 ± s.d. are shown. In parallel, two additional wells were transduced for each vector dilution to determine the percentage of EGFP-expressing cells, 2 days later. Functional titers (TU ml --1 ) were calculated as described. 13 The R 2 value of the regression analysis is 0.9825. Representative data of three independent experiments are shown. (b) MLV gamma retroviral vectors. S15-FRB-Bla1-containing MLV gamma retroviral vectors were produced, concentrated and titrated in the same way as described above, except that the vector stock was pre-diluted 70, 140, 280, 560 and 1120-fold. The R 2 value of the regression analysis is 0.985. Representative data of two independent experiments are shown. Bars #11 --12: Supernatants of cells transfected with a vector plasmid, and the pS15-FRB-Bla1 and pCEF-VSV-G plasmids. Supernatants were aliquoted and concentrated by ultracentrifugation. For freezethawing, the vectors were frozen in dry ice for 15 min. The frozen vectors were thawed in a 37 1C water bath and placed on wet ice as soon as the thaw was complete. After thawing, the concentrated vectors were diluted back to the original concentration. NT, not tested. Mock, no vector supernatant was added.
which were concentrated by ultracentrifugation through a 20% sucrose cushion and resuspended in 100th of the original volume. Unconcentrated and concentrated vectors were frozen and thawed once or twice or analyzed directly. To simplify the comparison of unconcentrated and concentrated vectors with or without freezing/thawing, vectors were diluted back to the original concentration first. All the samples were tested both using the rapid titration assay and an EGFP-based functional titration assay. As shown in Figure 7 , ultracentrifugation decreased the readout of the rapid titration assay (Figure 7a bar #1 vs bar #6) but only slightly decreased functional titers (Figure 7b bar #1 vs bar #6). Freezing and thawing did not cause significant changes in vector titers by either assay method, for both unconcentrated and concentrated vectors. Control vectors that did not contain VSV-G were negative in both assays, independent on whether the supernatant was concentrated by ultracentrifugation or not (Figure 7 panels a and b, bars #9 and #10) . Another control included the supernatant of cells transfected with the pS15-FRBBla1 and pCEF-VSV-G plasmid but without the packaging plasmid. These samples were also negative (Figure 7 panels a and b, bars #11 and #12).
DISCUSSION
This study reports on the development of a new titration assay for lentiviral and gamma retroviral vectors. The assay is rapid and can be finished within 8 h. The titers obtained using this rapid assay correlated well with the titers measured by EGFP-based functional transduction assays. Though the assay does not reveal functional vector titers, it eliminates one of the many factors that can contribute to the discrepancy between physical and functional vector titers in that fusion between the vector and target cells has to occur to register a signal in this assay. We expect this assay to be useful in the context of in vitro, ex vivo, or in vivo applications of lentiviral and gamma retroviral vectors, especially for vectors that need to be used fresh because their titers decrease upon freezing and thawing or after extended periods of storage. An attractive feature of this assay is that vector harvesting and titration can be carried out the same day, so that vectors can be used right away for transduction, avoiding potential issues with freezing and thawing.
A number of investigators have used full-length BLAK to monitor virus entry and virion fusion. Such applications were reported for HIV-1, influenza virus, Ebola virus and Marburg virus. For example, BLAK fused to the HIV-1 Vpr protein was used to examine HIV-1 virion fusion and entry 23 and to study Ebola virus glycoprotein-mediated entry in the context of Ebola viruspseudotyped HIV-1 virions. 24 It was also used with virus-like particles containing the influenza M1 protein tagged with BLAK (BlaM1) 25 to study virus entry, and with Ebola and Marburg virus using BLAK fused to the N-terminus of VP40. 26, 25 Although protein fragment complementation approaches have been studied extensively and are widely used, 27 such approaches have not been employed so far for vector titration or in virion-uptake studies.
The assay described in this study scores the uptake of vector particles by target cells. This is supported by the finding that transduction of HEK 293-Bla2 cells using Bla1-containing vectors preincubated using anti-VSV-G antibody did not result in blue fluorescence-emitting cells (Figure 5 ), presumably because BLAK activity was not restored, due to the lack of Bla1. It is also supported by the finding that vectors without VSV-G did not result in blue fluorescence-emitting cells (Figure 7a , bars #9 and #10). It is important to note, however, that vector uptake per se does not reflect functional vector titers because of the presence of defective vector particles that are generated during the production process. 28 For example, it has been shown that only a minority of HIV-1 virions that initiated reverse transcription formed proviruses, possibly due to defects in post entry steps. 29 Such vectors would still register a signal in this assay. It was encouraging to note, however, that the assay's readout (percentage of blue fluorescence-emitting cells) correlated well with functional titers, both for HIV-1 lentiviral vectors and for MLV gamma retroviral vectors ( Figure 6 ). The freeze/thaw cycle did not significantly decrease the assay's readout or the functional titers of the lentiviral vectors tested (Figure 7, panels A and B) . It was intriguing to note, however, that the readout for unconcentrated vectors was higher than that of concentrated vectors that had been diluted back to the original concentration (Figure 7a bar #1 vs bar #6) , while functional titers of the vectors were largely unaffected (Figure 7b bar #1 vs bar #6) . The reason for this selective loss in BLAK-based titers after concentration are presently not known.
According to the design of this new titration assay, Bla1 has to become part of the vector particle. When Bla1-containing vectors are used to transduce cells ex vivo or in vivo, they may also transduce antigen-presenting cells and immune responses against Bla1 may be induced. Animal studies are needed to confirm whether this will be a real concern or not.
How a vector is produced may directly affect the incorporation efficiency of S15-FRB-Bla1 and the ratio of physical and functional titers. Assay sensitivity also varies depending on the transduction method, transduction time and substrate-loading and -development times (Figure 4b ). Minimize the impact of these variables, one needs to establish and strictly follow standard operation procedures for vector production and titration.
To promote the incorporation of Bla1 into retroviral vector particles, the Bla1 fragment was fused to a universal membraneanchoring sequence (S15), 17, 18 a strategy that is expected to work for other enveloped viruses as well. It is important to note in this context that the incorporation of S15-FRB-Bla1 did not decrease the titers of HIV-1-based lentiviral vectors and MLV-based gamma retroviral vectors bearing the VSV-G glycoprotein.
In summary, the BLAK fragment complementation approach provides a useful strategy to titrate lentiviral and gamma retroviral vectors. Advantages of this strategy include that it reflects vector uptake by target cells, that the readouts correlate well with functional titers, and that it is rapid. We expect this assay to be useful for titrating lentiviral and retroviral vectors bearing alternative envelope glycoproteins. 30 It may also be useful for titrating other enveloped viruses and for studying virion uptake and membrane fusion dynamics.
MATERIALS AND METHODS

Plasmid constructs
The pS15-FRB-Bla1 plasmid encodes the N-terminal 15-aa sequence (S15) of c-Src, 17 a modified FKBP12 rapamycin-binding domain (FRB) of human mTOR kinase and the N-terminus of BLAK (Bla1, aa 26 --199) . 20 Plasmid pFKBP12-Bla2 encodes FKBP12 (FK506-binding protein) and the C-terminal fragment of BLAK (Bla2, aa 200 --263). 20 Both sequences were codonoptimized and synthesized by GenScript USA Inc. (Piscataway, NJ, USA), and cloned between the EcoRI and SalI sites of the pCEF vector containing the hybrid CEF promoter. 31, 32 Plasmid pBLAK-b encodes the wild-type BLAK. Plasmid pCMV-FKBP12-Bla2 was constructed by subcloning the EcoRI/SalI fragment derived from pFKBP12-Bla2 into a derivative of pEGFP-C1 (Clontech, Mountain View, CA, USA) that lacks an EGFP-coding region.
Cell culture HEK 293T cells (CRL-11268) and HEK 293 cells (CRL-1573) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and propagated in Dulbecco's Modified Eagle's Medium (DMEM, Lonza, Walkersville, MD, USA), supplemented with 10% heat-inactivated fetal bovine serum (FBS, Invitrogen, Carlsbad, CA, USA), 2 mM glutamine, 100 U ml --1 penicillin, and 100 mg ml --1 streptomycin (Invitrogen).
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Development of the HEK 293-Bla2 cell line HEK 293 cells were seeded in a 6-well plate at the density of 6 Â 10 5 cells per well and transfected the following day using 1 mg of pCMV-FKBP12-Bla2 and 13 ml of 7.5 mM PEI as described before. 35 One day after transfection, the cells were split 1:20 and a day later, G418 (Invitrogen) was added into the culture medium at a final concentration of 800 mg ml --1 . The culture medium was replaced with fresh medium supplemented with 800 mg ml --1 G418 every 5 days for a total of 20 days.
Production of lentiviral and gamma retroviral vectors
To produce S15-FRB-Bla1-containing lentiviral vectors, 9 Â 10 6 HEK 293T cells were seeded in 15-cm dishes using 20 ml of DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U ml --1 penicillin, and 100 mg ml --1 streptomycin. One day later, cells were transfected using 8.1 mg of the pNL(CMV)EGFP/CMV/WPREDU3 vector plasmid, 33 5.4 mg of the pCD/NL-BH*DDD packaging plasmid, 34 1.5 mg of the pCEF-VSV-G plasmid, 33 1.2 mg of the pS15-FRB-Bla1 plasmid and 195 ml of 7.5 mM PEI as described. 35 Three days later, vectors were collected and, when needed, the vectors were concentrated by ultracentrifugation using a 20% sucrose cushion and resuspended in PBS. 35 To produce S15-FRB-Bla1-negative lentiviral vectors, the pS15-FRB-Bla1 plasmid was omitted during transfection.
To produce MLV-based gamma retroviral vectors containing S15-FRBBla1 using PEI transfection, 9.4 mg of the pLEGFP-N1 vector plasmid (Clontech), 2.3 mg of the pMLV-GagPol packaging plasmid, 36 2.5 mg of the pCEF-VSV-G plasmid, and 2.0 mg of the pS15-FRB-Bla1 plasmid were used per 15-cm dish. Gamma retroviral vectors were harvested and concentrated in the same way as for the lentiviral vectors.
Western blot analysis of virion proteins
For western blotting, vector samples were concentrated by ultracentrifugation, as described above, and boiled using a solution containing 1 Â NuPAGE LDS sample buffer and 1 Â NuPAGE sample reducing agent (Invitrogen) for 5 min. The proteins were separated on a pre-cast NuPAGE 4 --12% Bis-Tris gel and transferred to PVDF membranes (Invitrogen). Membranes were blocked with 3% BSA overnight at 4 1C. They were then incubated with rabbit anti-b-lactamase antibody (Millipore, Billerica, MA, USA) or anti-HIV p24 monoclonal antibody 183-H12-5C 37 (obtained from Dr Bruce Chesebro and Kathy Wehrly through the NIH AIDS Research & Reference Reagent Program), or goat anti-MLV P30 antiserum (ATCC) for 90 min at room temperature on a rocker. Antibodies were pre-diluted 1:5000 in blotting solution (PBS supplemented with 0.05% Tween 20 (PBST) and 1% BSA). The membranes were washed twice with PBST, incubated with horseradish peroxidase-conjugated secondary antibody (Pierce, Rockford, IL, USA) pre-diluted 1:5000 in blotting solution for 45 min at room temperature on a rocker, and washed four times with PBST buffer. Membranes were incubated with the Western Lightning Plus Chemiluminescence Reagent (PerkinElmer, Waltham, MA, USA) and exposed to an X-ray film (Kodak's BioMax MR, Rochester, NY, USA) for 1 --5 min.
Vector titration using the BLAK fragment complementation assay A step-by-step outline of the assay is presented in Table 1 . To set up the assay, HEK 293-Bla2 target cells were seeded in 12-well plates at 1.2 Â 10 5 cells per well 30 --40 h before vector addition. For titration, the medium was replaced with 0.5 ml aliquots of serially diluted vector samples in DMEM supplemented with 10% FBS, 160 nM rapamycin and 8 mg ml --1 polybrene. Two wells were set up for each dilution. Following spinoculation at 1200 g for 0 --2 h at room temperature as specified in the figure legends, the cells were incubated in a CO 2 incubator for 0 --2 h. The cells were trypsinized, washed twice with PBS to get rid of bovine serum, resuspended in 0.5 ml of Substrate Loading Solution (CO 2 -independent medium, Invitrogen, supplemented with 0.2 or 1.0 mM CCF2-AM, Invitrogen). Cells were incubated in Substrate Loading Solution for 1 --2 h at room temperature, pelleted for 5 min at 500 g, resuspended in 0.5 ml of Development Medium (CO 2 -independent medium supplemented with 10% FBS and 2.5 mM probenecid), and incubated for 1 --2 h at room temperature. Cells were fixed by adding an equal volume of PBS supplemented with 2% formaldehyde, incubating them for 10 min, pelleting them for 5 min at 500 g and resuspending them in 0.5 ml PBS. For quantification, the cells were analyzed using a FACSCanto II system (BD Bioscience, Bedford, MA, USA). The mock controls were treated in exactly the same way except that there were no viral vectors present.
Determination of functional vector titers based on EGFP expression
HEK 293 cells were seeded in 12-well plates at 5 Â 10 4 cells per well the day before transduction. For transduction, the medium was replaced with 0.5 ml aliquots of serially diluted vector samples in DMEM supplemented with 10% FBS and 8 mg ml --1 polybrene. Two wells were set up for each dilution. Samples were processed and analyzed by FACS using a FACSCanto II system (BD Bioscience) and titers were calculated as described. 13 
